RET and medullary thyroid gland carcinoma: This report was extended by finding acquired mutations at RET G810 in three additional cases with RET-altered cancers progressing on selpercatinib: CCDC6-RET fusion NSCLC, RET fusion NSCLC and RET mutant MTC, respectively (Solomon et al. 2020) (Supplementary Table).